Zhejiang Beta Pharma is a leading pharmaceutical company primarily focused on the discovery, development and commercialization of new drugs to treat cancer, cardiovascular diseases and diabetes. The company is located in High Tech Park,Hangzhou with R&D center in Beijing.
Zhejiang Beta Pharma is a leading pharmaceutical company with focus on development and commercialization of new drugs for cancer, cardiovascular diseases and diabetes. Conmanna, an EGFR tyrosine kinase inhibitor, for cancer targeting therapy, is our leading compound. The preclinical studies have demonstrated its strong ability to inhibit a varieties of tumor cell growth and very low toxicity to tested animals. The clinical study will start as soon as it gets approval from SFDA.
Beta Pharma has a first-rate research team consisting of 20 multi-disciplined and dedicated professionals, including three American trained doctors. The team has full capacity to carry out the first class research for the new drug development, including chemical synthesis, screening, analysis, scale up, efficacy study, toxicity and safety evaluation and data management. Right now we have three new patented drugs in our pipeline.
We are also processing and marketing generic drugs in collaboration with other pharmaceutical companies including North China Pharma Group. The alliance has dramatically expanded our capacity both for manufacture and marketing.